Shu Yazaki

7PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Social epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 26, 2025
AlphaMissense for Identifying Pathogenic Missense Mutations in DNA Damage Repair Genes in Cancer.

Shu Yazaki, Xin Pei, Simon Powell

|Feb 11, 2025
Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer.

Rui Kitadai, Shu Yazaki, Aya Kuchiba

|Aug 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Rui Kitadai, Tatsunori Shimoi, Shu Yazaki

|Mar 11, 2024
Incidence of skeletal-related events in patients with Ewing sarcoma: An observational retrospective study in Japan.

Hisaki Aiba, Yuki Kojima, Tatsunori Shimoi

|Aug 04, 2023
Rare FGFR fusion genes in cervical cancer and transcriptome-based subgrouping of patients with a poor prognosis.

Kengo Hiranuma, Yuka Asami, Mayumi Kobayashi Kato

|Jul 12, 2023
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.

Hanae Ida, Toshio Shimizu, Makoto Nishino

Pageof 2

Frequent Collaborators

4 joint publications

Kan Yonemori

4 joint publications

Kazuki Sudo

3 joint publications

Rui Kitadai

2 joint publications

Yuki Kojima